Search for a trial

PROTECT: on-line adaptive proton therapy for cervical cancer to reduce the impact on morbidity and the immune system

Primary objective:- To determine the difference in mean dose (Gy) to pelvic bones (whole pelvic contour), and the difference in the mean V15Gy-bowelbag volume in cc (according to EMBRACE bowel bag definition) between photon and proton therapy in…

Use of mechanical left ventricular unloading in acute decompensated systolic heart failure complicated by cardiogenic shock

To assess the efficacy of early mechanical left ventricular unloading and standard of care (inotropes/vasopressors) versus inotropes/vasopressors alone (standard-of-care) in patients with ADHF and signs of cardiogenic shock.

First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

This study has been transitioned to CTIS with ID 2024-512639-58-00 check the CTIS register for the current data. ____________________PRIMARY OBJECTIVESFor Parts 1 and 2: To assess the safety and tolerability of BNT142 at all dose …

A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap, unresponsive to optimal symptomatic treatment

To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from Smouldering or Indolent SevereSystemic mastocytosis with handicap unresponsive to optimal symptomatic treatment.

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumabas First-line Treatment for Subjects with HER2+Metastatic Colorectal Cancer

To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…